Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Proposed risk factors for infection with multidrug-resistant pathogens in hemodialysis patients hospitalized with pneumonia

Contributed equally
BMC Infectious DiseasesBMC series – open, inclusive and trusted201717:681

https://doi.org/10.1186/s12879-017-2788-8

Received: 30 March 2017

Accepted: 4 October 2017

Published: 12 October 2017

Abstract

Background

In patients with hemodialysis-associated pneumonia (HDAP), information on both microbiologic features and antimicrobial strategies is limited. The aim of this study is to investigate predictive factors of infection with multidrug-resistant (MDR) pathogens in HDAP patients.

Methods

This was a multicenter, retrospective, and observational study. Enrolled patients were classified into MDR or non-MDR pathogens groups according to culture results. We examined risk factors of infection with MDR pathogens and created a decision support tool using these risk factors.

Results

MDR pathogens were identified in 24 (22.8%) out of a total of 105 HDAP patients. The most common MDR pathogens were methicillin-resistant Staphylococcus aureus (10 patients, 9.5%) and the isolation rate of Pseudomonas aeruginosa was 6.6%. Logistic regression showed two variables were associated with the isolation of MDR pathogens: recent hospitalization (adjusted odds ratio [OR]: 2.951, 95% confidence interval [CI]: 1.022–8.518) and PSI (Pneumonia Severity Index) score (adjusted OR: 1.023, 95% CI: 1.005–1.041). The optimal cut-off value for PSI score using a receiver operating characteristic curve analysis was 147. According to the presence of 0, 1, or 2 of the identified risk factors, the prevalence of MDR pathogens was 7.6, 28.2 and 64.2%, respectively (p < 0.001 for trend). The area under the curve of the prediction tool was 0.764 (95% CI: 0.652–0.875).

Conclusions

We demonstrated that recent hospitalization and PSI > 147 are risk factors of infection with MDR pathogens in HDAP patients. This simple proposed tool would facilitate more accurate identification of MDR pathogens in these patients.

Keywords

Pneumonia Hemodialysis End-stage renal disease Multidrug resistance Pathogen

Background

In hemodialysis (HD) populations, pneumonia is common and a leading cause of death [1, 2]. Because of the uremic internal milieu and the very frequent coexistence of serious comorbid medical conditions, these patients can be considered chronically immunosuppressed [3]. According to the United States Renal Dada System (USRDS) registry, approximately 20% of patients developed pneumonia in the 1-year period following initiation of dialysis therapy [1]. The mortality rates from pneumonia in hemodialysis (HD) patients were higher than those from pneumonia in the general population [2]. Therefore, early proper management is important to reduce mortality in HD patients with pneumonia.

Until now, there are no guidelines focused primarily on hemodialysis-associated pneumonia (HDAP). Because the 2005 American Thoracic Society (ATS)/Infectious Diseases Society of America (IDSA) guidelines included HDAP as a category of HCAP, HDAP patients could receive broad-spectrum antibiotics targeted against multidrug-resistant (MDR) pathogens [4]. But, several studies demonstrated that HCAP does not always identify MDR pathogens [5]. The 2016 ATS/IDSA guidelines removed the concept of HCAP among a category of nosocomial pneumonia [6].

The clinical epidemiology of HDAP has received little attention to date [7]. A previous study including some data used in the present study revealed that the HDAP group was clinically more similar to the CAP group than to the HCAP other than HDAP (O-HCAP) [7]. Accordingly, whether MDR pathogens-targeted antibiotics should be selected in patients with HDAP is unclear. Because of the uncertainty surrounding the actual risks of infection with MDR pathogens in HDAP patients and the increasing burden of end-stage renal disease worldwide [8], more data are required for a better distinct targeted therapeutic approach. Therefore, we investigated microbiologic characteristics and novel predictive factors of infection with MDR pathogens in patients hospitalized with HDAP. We also developed a prediction tool using these risk factors to identify subjects infected with MDR pathogens.

Methods

Study design, populations, and recorded parameters

We retrospectively conducted observational cohort studies at three institutions (Jeju National University Hospital, Kangbuk Samsung Hospital, and Ilsan Paik Hospital) between January 2011 and December 2015. Some of the clinical data for patients enrolled at Jeju National University Hospital were included in an article published in 2016 [7].

Patients were screened by the Korean Standard Classification of Diseases-7 codes of the followings; J18.0–18.9 as representative codes of pneumonia in the primary discharge diagnosis and N18.5, N18.9, or Z49.1 as codes of HD [9]. The medical records and radiological findings were reviewed to confirm the diagnosis of pneumonia by the following criteria: the presence of a new infiltrate on chest radiography with symptoms and signs of a lower respiratory tract infection. And patients on regular intermittent HD 3 times a week were included in the analysis. We excluded the following types of patients: (1) those who did not receive dialysis at the time of admission, (2) those who underwent continuous renal replacement therapy after organ failure developed by pneumonia, (3) those who had hospital-acquired pneumonia (HAP) developed at least 48 h after hospital admission, (4) those who did receive continuous ambulatory peritoneal dialysis, (5) those who re-visited within 10 days of discharging, and (6) those who transferred from other hospitals after hospitalization for >48 h.

According to culture results, enrolled patients were classified as MDR or non-MDR pathogens groups. We compared clinical characteristics, severity of pneumonia, identified pathogens, antibiotics, and clinical outcomes between the two groups. The severity of pneumonia was assessed by the CURB-65 (confusion, urea, respiratory rate, blood pressure, age more than 65 years) and Pneumonia Severity Index (PSI) scores [10, 11].

Definitions

HDAP was defined as pneumonia developing in patients receiving chronic HD within 30 days. O-HCAP was defined using the criteria of the 2005 ATS/IDSA guidelines as follows: recent history of hospitalization in an acute care hospital for ≥2 days in the past 90 days; residence in a nursing home or long-term care facility (NHAP, nursing home-acquired pneumonia); or recent outpatient intravenous therapy or wound care within the past 30 days [4]. Severe pneumonia was defined according to ATS/IDSA 2007 criteria [12].

In accordance with the 2005 ATS/IDSA guidelines [4], methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, extended-spectrum beta-lactamase (ESBL)-producing or carbapenem-resistant Klebsiella pneumoniae and Escherichia coli, Acinetobacter baumanii, and Stenotrophomonas maltophilia were considered to be MDR pathogens. According to susceptibility test criteria for lower respiratory tract pathogens, the appropriateness of antibiotic therapy was analyzed for all cases with an etiological diagnosis. Inappropriate antibiotic therapy was defined if the empirical antibiotics were not effective or unnecessarily broad against the identified pathogens based on in vitro susceptibility testing [13]. Failure of initial antibiotics therapy was defined as death during initial treatment or change of antibiotics from initial agents to others after 48 h due to clinical instability [14].

Microbiology

Sputum, tracheal aspirate, bronchial alveolar lavage fluid or blood samples were investigated for microbial analysis. Respiratory samples were cultured in a semi-quantitative manner, and pathogens were identified when a predominant microorganism was detected from group 4 or 5 sputum, according to Geckler’s grading system [15]. Blood cultures were considered as pathogens if there was no other infection source for a positive blood culture. Paired serology for Mycoplasma pneumoniae or Chlamydia pneumoniae and urinary antigen tests for Streptococcus pneumoniae and Legionella pneumophila serogroup 1 were also recorded if these exams were checked. The antibiotic sensitivity of all isolates was determined using a disc diffusion method, according to the Clinical and Laboratory Standards Institute guidelines [16].

Statistical analyses

Data are presented as medians and interquartile ranges (IQRs; 25th and 75th percentiles) for continuous variables and as numbers and percentages for categorical variables. For comparison of continuous variables, the Mann-Whitney U-test between two groups and the Kruskal-Wallis test among three groups were used to compare the median values. Categorical variables were compared using the Pearson χ2 test, and the Fisher’s exact test was used when any cell contained fewer than five data points.

To identify independent predictive factors associated with occurrence of MDR pathogens, we performed multivariate logistic regression analyses, as measured by the estimated odds ratio (OR) with 95% confidence interval (CI). Potential candidate variables with a P-value less than 0.05 in univariate analysis were entered into the regression model. From logistic regression results, we created predictive tool to identify patients with HDAP due to MDR pathogens. We classified patients based on the presence of risk factors for MDR pathogens. Then, we evaluated the predictive value of the proposed support tool for correctly indicating the presence of infection with MDR pathogens via a receiver operating characteristic (ROC) curve. The estimated area under the ROC curve (AUC) values were compared using the Hanley-McNeil test [17]. The cut-off point that showed the highest Youden Index was considered the optimal cut-off value [18]. All tests were two-sided, and P-values <0.05 were considered statistically significant. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) network version 18.0 (SPSS; Chicago, IL, USA).

Results

Baseline characteristics and clinical outcomes

A total of 887 patients were initially identified through medical records. Of these patients, 703 were excluded for the reasons in the followings; 536 did not meet pneumonia definitions, 111 did not receive dialysis at the time of admission, and 56 underwent CCRT after organ failure developed by pneumonia (Fig. 1). A total of 184 patients (21.1%) were enrolled as the dialysis related to pneumonia. Seventy-nine patients were excluded for the reasons presented in Fig. 1. Finally, a total of 105 patients were included in the present study.
Fig. 1

Patient flow. CRRT, continuous renal replacement therapy; HAP, hospital-acquired pneumonia; CAPD, continuous ambulatory peritoneal dialysis; HDAP, hemodialysis-associated pneumonia; MDR, multidrug-resistant

There were 68 males and 37 females, with a median age of 71 years. MDR pathogens were identified in 24 patients (22.8%). The baseline clinical characteristics and clinical outcomes of the total 105 HDAP patients are summarized in Table 1.
Table 1

Baseline clinical characteristics and treatment outcomes of patients admitted with hemodialysis-associated pneumonia

Characteristics

Overall patients (n = 105)

MDR pathogens group (n = 24)

Non-MDR pathogens group (n = 81)

P Value

Age (years)

71 (61–76)

73 (62–79)

71 (61–76)

0.199

Male

68 (64.8%)

15 (62.5%)

53 (65.4%)

0.792

Female

37 (35.2%)

9 (37.5)

28 (34.6%)

0.792

Time interval between dialysis and pneumonia (months)

30 (11–69)

21 (10–74)

34 (12–69)

0.541

Etiology of dialysisa

    

 Diabetes mellitus

60 (57.1%)

14 (58.3%)

46 (56.7%)

0.344

 Hypertension

57 (54.2%)

11 (45.8%)

46 (56.7%)

0.893

 Glomerulonephropathy

6 (5.7%)

1 (4.1%)

5 (6.1%)

1.000

 Idiopathic

7 (6.6%)

2 (8.3%)

5 (6.1%)

0.658

 Others

13 (12.3%)

1 (4.1%)

12 (14.8%)

0.289

Tube feeding

9 (8.5%)

5 (20.8%)

4 (4.9%)

0.028

HCAP criteria other than HDAP

 

17 (70.8%)

27 (33.3%)

0.001

 Recent hospitalization

42 (40.0%)

16 (66.6%)

26 (32.0%)

0.002

 NHAP

10 (9.5%)

5 (20.8%)

5 (6.1%)

0.047

 Recent intravenous therapy

10 (9.5%)

3 (12.5%)

7 (8.6%)

0.692

Clinical parameters

    

 Severe pneumonia

37 (35.2%)

13 (54.1%)

24 (29.6%)

0.027

 Confusion

15 (14.2%)

6 (25.0%)

9 (11.1%)

0.103

 Respiratory failure

47 (44.7%)

14 (58.3%)

33 (40.7%)

0.128

 Sepsis or septic shock at onset

15 (14.2%)

7 (29.1%)

8 (9.8%)

0.040

 ICU admission

22 (20.9%)

10 (41.6%)

12 (14.8%)

0.005

 Need for ventilator

6 (5.7%)

3 (12.5%)

3 (3.7%)

0.131

Radiological findings

    

 Multi-lobar involvement

73 (69.5%)

20 (83.3%)

53 (65.4%)

0.094

 Pleural effusion

33 (31.4%)

6 (25.0%)

27 (33.3%)

0.440

Laboratory findings

    

 WBC (/mm3)

11,200 (7400–15,015)

13,210 (8200–18,600)

10,680 (7150–14,960)

0.104

 CRP (mg/dl)

8.5 (3.7–15.1)

9.4 (4.8–16.0)

7.1 (3.7–14.7)

0.364

 Procalcitonin, n = 62, (mg/dl)

1.1 (0.4–5.9)

1.7 (0.5–6.8)

0.9 (0.3–5.6)

0.571

Indices for disease severity

    

 CURB-65 score

2 (1–2)

2 (1–3)

2 (1–2)

0.095

 CURB-65 score ≥ 3

19 (18.0%)

7 (29.1%)

12 (14.8%)

0.133

 PSI score

123 (105–145)

148 (120–181)

118 (99–139)

0.001

 PSI class IV or V

91 (86.6%)

23 (95.8%)

68 (83.9%)

0.181

Initial antibiotic therapy

    

 as CAP

47 (44.7%)

4 (16.6%)

43 (53.0%)

0.002

 as HAP

58 (55.2%)

20 (83.3%)

38 (46.9%)

0.002

 Use of Anti-MRSA agents

7 (6.6%)

4 (16.6%)

3 (3.7%)

0.046

Clinical outcomes

    

 Use of inappropriate antibiotics

21 (20.0%)

15 (62.5%)

6 (7.4%)

<0.001

 Change of initial antibiotics

40 (38.0%)

13 (54.1%)

27 (33.3%)

0.065

 Failure of initial antibiotics therapy

29 (27.6%)

11 (45.8%)

18 (22.2%)

0.254

 Duration of antibiotic therapy (days)

12 (10–15)

12 (9–22)

12 (10–15)

0.401

 Length of hospital stay (days)

11 (7–17)

14 (9–25)

11 (7–16)

0.093

 Pneumonia-related mortality rate

8 (7.6%)

6 (25.0%)

2 (2.4%)

0.002

 Hospital mortality rate

11 (10.4%)

6 (25.0%)

5 (6.1%)

0.016

Data are presented as median (interquartile range) or number (%)

MDR multidrug-resistant, HCAP healthcare-associated pneumonia, HDAP hemodialysis-associated pneumonia, NHAP nursing home-acquired pneumonia, ICU intensive care unit, WBC white blood cell, CRP C-reactive protein, CAP community-acquired pneumonia, MRSA methicillin-resistant Staphylococcus aureus, CURB-65 Confusion, Urea, Respiratory rate, Blood pressure, Age ≥ 65, PSI Pneumonia Severity Index

aallowed for overlap

Microbiological etiology

Table 2 shows the distribution of causative organisms. Of the total 105 HDAP patients, the responsible pathogens were determined only in 53 patients (50.4%). The most common pathogen was S. aureus (17, 16.1%), which consisted of methicillin-sensitive S. aureus (7, 6.6%) and MRSA (10, 9.5%), followed by K. pneumoniae (11, 10.4%) and S. pneumoniae (10, 9.5%). The isolation rates of drug-resistant gram-negative bacteria P. aeruginosa, A. baumanii, ESBL-producing K. pneumoniae were 6.6, 5.7, and 2.8%, respectively.
Table 2

Microorganisms identified in patients admitted with hemodialysis-associated pneumonia

Microorganismsa

No. of patients (%)

Identified microorganismsb

Gram-positive bacteria

53 (50.4%)

Streptococcus pneumoniae

10 (9.5%)

Staphylococcus aureus

17 (16.1%)

  MSSA

7 (6.6%)

  MRSA

10 (9.5%)

Gram-negative bacteria

 

Pseudomonas aeruginosa

7 (6.6%)

Haemophilus influenza

0 (0%)

Klebsiella pneumoniae

11 (10.4%)

  ESBL (+)

3 (2.8%)

  ESBL (−)

8 (7.6%)

Acinetobacter baumannii

6 (5.7%)

Stenotrophomonas maltophilia

1 (0.9%)

Mycoplasma pneumonia

2 (1.9%)

 Other gram-negative speciesc

5 (4.7%)

Polymicrobial pathogens

8 (7.6%)

Multidrug-resistant pathogensd

24 (22.8%)

Data are presented as number (%)

HDAP: hemodialysis-associated pneumonia; MSSA: methicillin-sensitive Staphylococcus aureus; MRSA: methicillin-resistant Staphylococcus aureus

aAllowed for overlap

bOne or more pathogens may be listed

cOther gram-negative species include Escherichia coli, Enterobacter species, Serratia marcescens, and Legionella pneumophilia

dMultidrug-resistant pathogens include Methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas species, Acinetobacter species, Stenotrophomonas maltophilia, and extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae

Predictive factors associated with occurrence of MDR pathogens

Table 3 shows multivariate logistic regression analyses of the four risk factors for MDR pathogens: tube feeding, recent hospitalization, NHAP, and PSI score. Recent hospitalization and PSI score was independently associated with the isolation of MDR pathogens in HDAP patients (adjusted OR: 2.951, 95% CI: 1.022–8.518, p = 0.045 and adjusted OR: 1.023, 95% CI: 1.005–1.041, p = 0.011, respectively). ROC curve analysis was used to assess optimal cutoff values for PSI score. The maximum sum of sensitivity and specificity was 147 for PSI (sensitivity 54.1%, specificity 85.1%, positive predictive value 52.0%, and negative predictive value 86.2%, Fig. 2).
Table 3

Multivariate logistic regression analysis for predictive factors associated with multidrug-resistant pathogens in patients admitted with hemodialysis-associated pneumonia

Risk factors

Odds ratio (95% confidence interval)

P Value

Tube feeding

2.229 (0.459–10.819)

0.320

Recent hospitalization

2.951 (1.022–8.518)

0.045

NHAP

3.535 (0.823–15.183)

0.090

PSI score

1.023 (1.005–1.041)

0.011

NHAP nursing home-acquired pneumonia, PSI Pneumonia Severity Index

Fig. 2

Comparison of receiver-operating characteristic (ROC) curves between the proposed tool and PSI score to predict infection with multidrug-resistant pathogens. PSI, pneumonia severity index

Proposed decision support tool for prediction of MDR pathogens

Based on the multivariate logistic regression analysis of the association with occurrence of MDR pathogens in patients with HDAP, PSI score > 147 and recent hospitalization were considered as predictive MDR risk factors. We created a decision support tool to predict MDR pathogens. Patients divided into low (without any risk factors)-, intermediate (with only one risk factor) -, and high (with both two risk factors)-risk strata based on two predictive MDR risk factors.

The ROC curves for prediction tool and PSI score are shown in Fig. 2 The prediction tool had a higher discriminatory power to identify MDR pathogen infection than PSI score, although there was no statistically significant difference (p = 0.228). The area under the curve (AUC) of the prediction tool (AUC: 0.764, 95% CI: 0.652–0.875, p < 0.001) tended to be greater than that of the PSI score (AUC: 0.718, 95% CI: 0.593–0.842, p = 0.001) (p = 0.236). The optimal cutoff for the prediction tool was 1 (sensitivity 83.3%, specificity 59.3%, positive predictive value 37.7%, and negative predictive value 92.3%). According to the risk stratification based on number of MDR risk variables, the prevalence of MDR pathogens was 7.6, 28.2 and 64.2%, respectively (p < 0.001 for trend, Table 4 and Fig. 3).
Table 4

Proposed prediction tools for multidrug-resistant pathogens in patients admitted with hemodialysis-associated pneumonia

Risk of MDR pathogens

Predictive factors

No. of patients

No. (%) of patients isolated with MDR pathogens

Low

PSI score ≤ 147 and no recent hospitalization

52

4 (7.6%)

Moderate

PSI score > 147 or recent hospitalization

39

11 (28.2%)

High

PSI score > 147 and recent hospitalization

14

9 (64.2%)

MDR multidrug-resistant, PSI Pneumonia: Severity Index

Fig. 3

The probability of MDR pathogens stratified by risk using the prediction tool. MDR, multidrug-resistant

Discussion

The current study revealed that 22.8% of hospitalized patients with HDAP had MDR pathogens. We also demonstrated that the occurrence of MDR pathogens was significantly associated with recent hospitalization within 3 months and PSI score more than 147. On the basis of these findings, we proposed a simple predictive tool to determine the risk of infection with MDR pathogens in HDAP using the number of risk factors. As the number of risk factors increased, the prevalence of infection with MDR pathogens also increased (low - 7.6%, intermediate - 28.2% and high - 64.2%, respectively; p < 0.001 for trend). Overall, this model had moderate predictive value, as demonstrated by the ROC curve (AUC: 0.764, 95% CI: 0.652–0.875). To our knowledge, this is the first study that proposes evidence based tool to predict infection with MDR pathogens among HDAP patients.

Previous studies have demonstrated that the isolation rate of MDR pathogens shows interregional differences in HCAP patients [5]. Also, HCAP consists of very heterogeneous subgroups [4], and there is little evidence that all criteria for HCAP convey similar risks for infection with MDR pathogens. This contributed to the removal of the concept of HCAP in the new 2016 ATS/IDSA guidelines for management of HAP and ventilator-associated pneumonia [6]. But, the concept of HCAP as a separate clinical entity would be still valid, because frequent interactions with the healthcare system can have potential risk for MDR pathogens [6]. Discordant results about the isolated rate of MDR pathogens among previous studies may be caused by the fact that the concept of HCAP includes various criteria for heterogeneous conditions [4], which did not have similar risks for infection with MDR pathogens [19]. Among the category of HCAP, only NHAP have been studied considerably, and MDR pathogens were not frequently isolated in these patients [2025]. In contrast, the previous studies on HCAP included a relatively small proportion of 2.5~10.4% of HDAP patients [7, 13, 2629]. Therefore, it is not known whether it is desirable to actively apply the guideline-concordant treatment to all patients with HDAP [4].

There are few studies focusing on the actual risk of MDR pneumonia in HDAP patients, resulting in a lack of microbiologic data on HDAP as a different category of HCAP. Although most HD patients live outside of hospitals, they manifest various degrees of immunodeficiency, regularly visit the hospital, and receive ongoing healthcare more often than non-HD patients. Compared to the general population, these characteristics of HD patients may contribute to the high incidence of MDR pathogens, which is not related to HD itself. Therefore, there is a question regarding whether all patients with HDAP should receive antibiotic therapy against MDR pathogens [30, 31].

We found two large cohort studies using the USRDS registry for clinical epidemiology of HDAP patients and four retrospective studies applying to the concept of HDAP [1, 2, 7, 3032]. Unfortunately, in large cohort studies, the microorganisms in more than 80% of the patients hospitalized with HDAP could not be identified [1, 2]. The detection rate of P. aeruginosa was about 2%, but the rate of total isolated MDR pathogens was not mentioned in either study [1, 2]. In addition, four retrospective studies have demonstrated inconsistent MDR pathogen distributions in HDAP patients [7, 3032]. In line with previous HDAP studies, the rate of isolated MDR pathogens was 5.6 to 35.4%, although microorganisms could not be identified in most patients. The detection rates of MRSA, P. aeruginosa, and A. baumanii were 0%~27.5%, 1.6%~16.7%, and 0%~4.2%, respectively [7, 3032]. In the present study, MDR pathogens were identified in 22.8% of cases; of these, the most frequent microorganisms were MRSA (9.5%), followed by P. aeruginosa (6.6%), A. baumanii (5.7%). However, the rates of isolated MDR pathogens in previous studies and this study revealed a variable incidence range [7, 3032].

Although we cannot offer satisfactory explanations for these various incidence rates of MDR pathogen distribution, these discordant results may be related to whether the selected populations included the other criteria for HCAP. The studies demonstrating relatively low MDR pathogen infections included patients who only met HDAP criterion without O-HCAP components for HCAP classification [7, 31]. On the contrary, the remaining studies enrolled patients who included the other criteria for HCAP, and reported relatively high incidence of MDR pathogens [30, 32]. In line with this concept, among 61 patients who only met HDAP criterion without the other criteria for HCAP in our study, the isolated rate of MDR pathogens was relatively low (7 patients, 11.4%). We also demonstrated that presence of O-HCAP components exhibited higher occurrence of MDR pathogens in patients with HDAP. Among the O-HCAP category, recent hospitalization and NHAP were more frequently observed in the MDR pathogens group. Especially, recent hospitalization was independently associated with the isolation of MDR pathogens in multivariable analysis. Therefore, our study found that MDR pathogen infection in HDAP could be associated with recent hospitalization, rather than HD status itself, similar to previous studies [19, 26]. The present study revealed that PSI score than 147 was also significantly associated with HDAP caused by MDR pathogens. Furthermore, the proposed prediction tool using these two risk factors showed a moderate discriminatory power for risk stratification for an infection with MDR pathogens in HDAP patients. Therefore, our findings could be helpful in physicians’ decisions to select HDAP patients who need to be treated for MDR pathogens.

The present study has several limitations. Firstly, the main limitation of this study is retrospective design. Because the effect of missing data in the results is unknown, our study may be vulnerable to selection bias. And a small sample size did not allow us to draw a robust conclusion. We were unable to enroll a large number of HDAP patients despite the fact that they were collected from three centers over 5 years. Larger studies are needed to validate our results and to strengthen the power to identify risk factors of MDR pathogens. Secondly, the microbiological etiology could be identified in only about 50% of enrolled patients. Possible reasons for low detections would include an inability to collect lower respiratory tract specimens, prior antibiotic use before specimen collection, insensitive diagnostic tests for known pathogens, a lack of testing for other recognized pathogens such as coxiella, unknown pathogens, and possible noninfectious causes such as aspiration pneumonitis [33]. Thirdly, median age of the patients is 71 years in the present study. Aging is associated with declines in adaptive and innate immunity [34]. Infections occur more frequently in the elderly, and the age-related remodeling of the immune system plays any role in the development of HDAP or HDAP with MDR pathogens [34]. Although age was not associated with the isolation of MDR pathogens among HDAP patients in our study, the results might be biased towards the old age population. Finally, the analysis for distribution of MDR pathogens included entire study populations with culture-negative pneumonia. Thus, we may have skewed our findings in that the true incidence of MDR pathogens could have been underestimated. In this study, we founded two independent risk factors for occurrence of MDR pathogens in patients with HDAP. And the prevalence of MDR pathogens was <10% in patients without one of these risk factors. If validated in subsequent multicenter studies, this prediction rule could potentially assist clinicians who are deciding on whether to administer anti-MRSA or anti-pseudomonal therapy to patients with HDAP.

Conclusion

This multicenter, retrospective, observational study offers the findings of the clinical epidemiology, microbiology, and predictive factors of MDR pathogens in patients with HDAP. The HDAP concept itself as an HCAP has limited value in selecting patients harboring MDR pathogens. It could be necessary to stratify the patients with regard to risk factors in order to properly identify infection with MDR pathogens. Although large-scale prospective studies are needed to confirm our results, our findings would be helpful for physicians’ decisions to select HDAP patients harboring MDR pathogens.

Abbreviations

A. baumannii

Acinetobacter baumannii

ATS/IDSA: 

American Thoracic Society/Infectious Diseases Society of America

CAP: 

community-acquired pneumonia

CRP: 

C-reactive protein

CURB-65: 

Confusion, Urea, Respiratory rate, Blood pressure, Age ≥ 65

ESBL: 

Extended-spectrum b-lactamase

HAP: 

Hospital-acquired pneumonia

HCAP: 

Healthcare-associated pneumonia

HD: 

Hemodialysis

HDAP: 

Hemodialysis-associated pneumonia

ICU: 

Intensive care unit

K. pneumoniae

Klebsiella pneumoniae

MDR: 

Multidrug-resistant

MRSA: 

Methicillin-resistant Staphylococcus aureus

NHAP: 

Nursing home-acquired pneumonia

O-HCAP: 

The HCAP other than HDAP

P. aeruginosa

Pseudomonas aeruginosa

PSI: 

Pneumonia Severity Index

S. aureus

Staphylococcus aureus

S. pneumoniae

Streptococcus pneumoniae

USRDS: 

The United States Renal Dada System

WBC: 

White blood cell

Declarations

Acknowledgements

Nil.

Funding

This study was funded by a research grant from Chong Kun Dang Corp.

Availability of data and materials

All the data supporting our findings are contained within the manuscript.

Authors’ contributions

J-US and HKP contributed to the study design, data acquisition, and writing of the manuscript. HKK contributed to data acquisition, and data interpretation. JL contributed to the study design, data acquisition, data interpretation, statistical analysis, writing of the manuscript, and is responsible for the study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study protocol was approved by the Ethical Review Committee of Jeju National University Hospital (IRB number, 2015–07-005). Informed consent was waived because of the retrospective nature of the study.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
(2)
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine
(3)
Department of Internal Medicine, Jeju National University Hospital, Jeju National University School of Medicine

References

  1. Guo H, Liu J, Collins AJ, Foley RN. Pneumonia in incident dialysis patients--the United States renal data system. Nephrol Dial Transplant. 2008;23:680–6.View ArticlePubMedGoogle Scholar
  2. Slinin Y, Foley RN, Collins AJ. Clinical epidemiology of pneumonia in hemodialysis patients: the USRDS waves 1, 3, and 4 study. Kidney Int. 2006;70:1135–41.View ArticlePubMedGoogle Scholar
  3. Vanholder R, Ringoir S. Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review. J Am Soc Nephrol. 1993;3:1541–54.PubMedGoogle Scholar
  4. American Thoracic Society. Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.View ArticleGoogle Scholar
  5. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis. 2014;58:330–9.View ArticlePubMedGoogle Scholar
  6. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of Adults with Hospital-Acquired and Ventilator-Associated Pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63:e61–e111.View ArticlePubMedPubMed CentralGoogle Scholar
  7. Lee JH, Moon JC. Clinical characteristics of patients with hemodialysis-associated pneumonia compared to patients with non-hemodialysis community-onset pneumonia. Respir Med. 2016;111:84–90.View ArticlePubMedGoogle Scholar
  8. Lee YK, Kim K, Kim DJ. Current status and standards for establishment of hemodialysis units in Korea. Korean J Intern Med. 2013;28:274–84.View ArticlePubMedPubMed CentralGoogle Scholar
  9. Korean Standard Statistical Classification. The standard of classification of disease and cause of death [Internet]. Daejeon, Korea; Korean Standard Statistical Classification; 2016 [cited at 2017 Aug 11]. Available from: https://kssc.kostat.go.kr:8443/ksscNew_web/link.do?gubun=AQ5004.
  10. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82.View ArticlePubMedPubMed CentralGoogle Scholar
  11. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. New Engl J Med. 1997;336:243–50.View ArticlePubMedGoogle Scholar
  12. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(Suppl 2):S27–72.View ArticlePubMedGoogle Scholar
  13. Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007;51:3568–73.View ArticlePubMedPubMed CentralGoogle Scholar
  14. Maruyama T, Fujisawa T, Okuno M, Toyoshima H, Tsutsui K, Maeda H, et al. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy. Clin Infect Dis. 2013;57:1373–83.View ArticlePubMedGoogle Scholar
  15. Geckler RW, Gremillion DH, McAllister CK, Ellenbogen C. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates. J Clin Microbiol. 1977;6:396–9.PubMedPubMed CentralGoogle Scholar
  16. Clinical and Laboratory Standards Institute: Methods for Dilution Antimicrobial Susceptiblity Tests for Bacteria That Grow Aerobically; Approved Standard-Eighth Edition. Clin Lab Stand Inst 2008;29:M07-A08.Google Scholar
  17. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36.View ArticlePubMedGoogle Scholar
  18. Bewick V, Cheek L, Ball J. Statistics review 13: receiver operating characteristic curves. Crit Care. 2004;8:508–12.View ArticlePubMedPubMed CentralGoogle Scholar
  19. Shorr AF, Zilberberg MD, Micek ST, Kollef MH. Prediction of infection due to antibiotic-resistant bacteria by select risk factors for health care-associated pneumonia. Arch Intern Med. 2008;168:2205–10.View ArticlePubMedGoogle Scholar
  20. Ewig S, Klapdor B, Pletz MW, Rohde G, Schutte H, Schaberg T, et al. Nursing home-acquired pneumonia in Germany: an 8-year prospective multicentre study. Thorax. 2012;67:132–8.View ArticlePubMedGoogle Scholar
  21. Ma HM, Wah JL, Woo J. Should nursing home-acquired pneumonia be treated as nosocomial pneumonia? J Am Med Dir Assoc. 2012;13:727–31.View ArticlePubMedGoogle Scholar
  22. Polverino E, Dambrava P, Cilloniz C, Balasso V, Marcos MA, Esquinas C, et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax. 2010;65:354–9.View ArticlePubMedGoogle Scholar
  23. Nakagawa N, Saito Y, Sasaki M, Tsuda Y, Mochizuki H, Takahashi H. Comparison of clinical profile in elderly patients with nursing and healthcare-associated pneumonia, and those with community-acquired pneumonia. Geriatr Gerontol Int. 2014;14:362–71.View ArticlePubMedGoogle Scholar
  24. Liapikou A, Polverino E, Cilloniz C, Peyrani P, Ramirez J, Menendez R, et al. A worldwide perspective of nursing home-acquired pneumonia compared with community-acquired pneumonia. Respir Care. 2014;59:1078–85.View ArticlePubMedGoogle Scholar
  25. Koh SJ, Lee JH. Clinical characteristics of nursing home-acquired pneumonia in elderly patients admitted to a Korean teaching hospital. Korean J Intern Med. 2015;30:638–47.View ArticlePubMedPubMed CentralGoogle Scholar
  26. Jung JY, Park MS, Kim YS, Park BH, Kim SK, Chang J, et al. Healthcare-associated pneumonia among hospitalized patients in a Korean tertiary hospital. BMC Infect Dis. 2011;11:61.View ArticlePubMedPubMed CentralGoogle Scholar
  27. Chalmers JD, Taylor JK, Singanayagam A, Fleming GB, Akram AR, Mandal P, et al. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. Clin Infect Dis. 2011;53:107–13.View ArticlePubMedGoogle Scholar
  28. Shindo Y, Sato S, Maruyama E, Ohashi T, Ogawa M, Hashimoto N, et al. Health-care-associated pneumonia among hospitalized patients in a Japanese community hospital. Chest. 2009;135:633–40.View ArticlePubMedGoogle Scholar
  29. Zilberberg MD, Shorr AF, Micek ST, Mody SH, Kollef MH. Antimicrobial therapy escalation and hospital mortality among patients with health-care-associated pneumonia: a single-center experience. Chest. 2008;134:963–8.View ArticlePubMedGoogle Scholar
  30. Kawasaki S, Aoki N, Kikuchi H, Nakayama H, Saito N, Shimada H, et al. Clinical and microbiological evaluation of hemodialysis-associated pneumonia (HDAP): should HDAP be included in healthcare-associated pneumonia? J Infect Chemother. 2011;17:640–5.View ArticlePubMedGoogle Scholar
  31. Taylor SP, Taylor BT. Health care-associated pneumonia in haemodialysis patients: clinical outcomes in patients treated with narrow versus broad spectrum antibiotic therapy. Respirology. 2013;18:364–8.View ArticlePubMedGoogle Scholar
  32. Wang PH, Wang HC. Risk factors to predict drug-resistant pathogens in hemodialysis-associated pneumonia. BMC Infect Dis. 2016;16:377.View ArticlePubMedPubMed CentralGoogle Scholar
  33. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–27.View ArticlePubMedPubMed CentralGoogle Scholar
  34. Fuentes E, Fuentes M, Alarcón M, Palomo I. Immune system dysfunction in the elderly. An Acad Bras Cienc. 2017;89:285–99.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2017